文献速递垂体与肾上腺疾病糖尿病肥胖与代谢综合征

内源性库欣综合征患者GLP-1受体激动剂暴露与恶性肿瘤风险

Glucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing's syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

以色列全国性队列研究纳入2000至2023年诊断的内源性库欣综合征患者609例,评估GLP-1受体激动剂(GLP-1RA)暴露与 incident 恶性肿瘤的关联。平均随访14.7±6.4年,137例(22.5%)接受GLP-1RA治疗,暴露者与未暴露者癌症发病率分别为17.59与12.50/1000人年;时变竞争风险分析显示GLP-1RA暴露与恶性肿瘤风险升高无关(HR 1.65,95%CI 0.94-2.90;校正后HR 1.22,95%CI 0.45-3.29)。

要点

  • 库欣综合征患者中GLP-1RA暴露未增加恶性肿瘤风险
  • 暴露者癌症发病率为17.59/1000人年,未暴露者为12.50/1000人年
  • 时变分析HR 1.65(95%CI 0.94-2.90),校正后结果一致

核心结论

  • 在内源性库欣综合征患者中,GLP-1RA暴露与恶性肿瘤风险改变无关。
  • 结果为该高危人群使用GLP-1RA的肿瘤安全性提供了令人安心的证据。

研究设计与样本

  • 以色列Clalit健康服务数据库的全国性队列研究,纳入2000至2023年诊断的内源性库欣综合征患者。
  • 排除肾上腺癌或异位库欣综合征患者;GLP-1RA暴露定义为≥3次处方配药,并作为时变变量建模。
  • 队列共609例,平均年龄±SD为48.05±17.17岁,女性占65.02%。

主要发现

  • 平均随访14.7±6.4年期间,116例发生癌症,141例死亡。
  • 137例(22.5%)接受GLP-1RA治疗;未暴露与暴露人年分别为8159.69和795.88。
  • 癌症发病率在未暴露者为12.50/1000人年,暴露者为17.59/1000人年。
  • 时变竞争风险分析中GLP-1RA暴露与恶性肿瘤风险无关(HR 1.65;95%CI 0.94-2.90),校正后HR 1.22(95%CI 0.45-3.29)。
  • 12个月滞后分析及按缓解分层分析结果一致。

关键数值与推荐

  • GLP-1RA暴露定义:≥3次处方配药。
  • 主要结局:库欣综合征诊断后 incident 恶性肿瘤,比较暴露与未暴露患者。
  • 敏感性分析包括12个月滞后法及按缓解状态分层。

临床怎么用

  • 对合并糖尿病或肥胖的内源性库欣综合征患者,GLP-1RA暴露未显示增加恶性肿瘤风险。
  • 该结果可为此类高危人群的临床用药决策提供肿瘤安全性参考。

局限性

  • 原文摘要未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with endogenous Cushing's syndrome (CS) have increased malignancy risk. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for diabetes and obesity, yet their oncologic outcomes in CS remains limited. OBJECTIVE: The objective of this study was to evaluate the association between GLP-1RA exposure and incident malignancy in patients with CS. METHODS: This was a nationwide cohort study using the Clalit Health Services database in Israel, including patients with endogenous CS diagnosed between 2000 and 2023. Patients with adrenal carcinoma or ectopic CS were excluded. Glucagon-like peptide-1 receptor agonist exposure was defined as ≥3 prescription dispensations and modeled as a time-varying variable. The main outcome was incident malignancy following a CS diagnosis in GLP-1RA-exposed vs nonexposed patients. Sensitivity analyses included a 12-month lag-period approach and stratification by remission. RESULTS: The cohort included 609 patients with CS (mean age ± SD, 48.05 ± 17.17 years; 65.02% women). During a mean follow-up of 14.7 ± 6.4 years, 116 patients developed cancer and 141 died. Overall, 137 patients (22.5%) received GLP-1RA therapy. A total of 8159.69 nonexposed and 795.88 exposed person-years were accrued, with cancer incidence rates of 12.50 and 17.59 per 1000 person-years, respectively. In time-varying competing risk analysis, GLP-1RA exposure was not associated with increased malignancy risk (hazard ratio [HR] 1.65; 95% CI, 0.94-2.90), with consistent results after adjustment (adjusted HR 1.22; 95% CI, 0.45-3.29). Findings were similar in lag-period and remission-stratified analyses. CONCLUSION: In this nationwide cohort of patients with CS, GLP-1RA exposure was not associated with altered malignancy risk. These findings provide reassuring evidence regarding the oncologic safety of GLP-1RAs in this high-risk population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Dotan I, Shochat T, Kushnir S, et al. Glucagon-like peptide-1 receptor agonist exposure and malignancy risk in patients with endogenous Cushing's syndrome. J Clin Endocrinol Metab. 2026. PMID: 42233686. doi:10.1210/clinem/dgag223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。